Daniel R. Passeri's Insider Trades & SAST Disclosures
Daniel R. Passeri's most recent trade in Cue Biopharma Inc was a trade of 450,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daniel R. Passeri.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | R. Daniel Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 16 Dec 2024 | 30,000 | 164,578 (0%) | 0% | 1.0 | 30,900 | Common Stock |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 14 Aug 2023 | 3,000 | 134,578 (0%) | 0% | 2.9 | 8,580 | Common Stock |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2023 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 324,000 | 324,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 75,000 | 173,700 (0%) | 0% | - | Common Stock | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 75,000 | 0 | - | - | Restricted Stock Units | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 31 Mar 2022 | 32,122 | 141,578 (0%) | 0% | 4.9 | 156,755 | Common Stock |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2022 | 10,000 | 131,578 (0%) | 0% | 0 | Common Stock | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2021 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2021 | 75,000 | 130,377 (0%) | 0% | - | Common Stock | |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.57 per share. | 30 Sep 2021 | 31,677 | 98,700 (0%) | 0% | 14.6 | 461,534 | Common Stock |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 14.72 per share. | 24 Sep 2021 | 3,400 | 55,377 (0%) | 0% | 14.7 | 50,051 | Common Stock |
| Cue Biopharma Inc | Daniel R. Passeri | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 85,000 | 85,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges